

**Assessing the Age Specificity  
of Infection Fatality Rates for COVID-19:  
Systematic Review, Meta-Analysis,  
and Public Policy Implications**

**Supplementary Appendix**

Andrew T. Levin, Gideon Meyerowitz-Katz, Nana Owusu-Boaitey,  
Kensington B. Cochran, and Seamus P. Walsh

27 August 2020

## Supplementary Appendix A: PRISMA Checklist

Section/topic	#	Checklist item	Page #
<b>TITLE</b>			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	Title Page
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	Title Page
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known.	1-2
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	1-2
<b>METHODS</b>			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	NA
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	2
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	2, App.B
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	App. B
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, included in the meta-analysis).	2-5, App. D
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	2, App. F
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	2-5
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies and how this information is to be used in any data synthesis.	2-5
Summary measures	13	State principal summary measures.	1-5
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency.	5, App. G
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	5, App. G
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	5, App. G

<b>RESULTS</b>			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	6, 9-10, App. H
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	7-9, App. F
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	App. I
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	14-16
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	11-13
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	App. J
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	App. K
<b>DISCUSSION</b>			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups.	9-10
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	18
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	17-18
<b>FUNDING</b>			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	Title Page

Source: Moher et al. (2009).<sup>1</sup>

## **Supplementary Appendix B: Meta-analysis search procedure**

To perform the present meta-analysis, we collected published papers and preprints regarding the seroprevalence and/or infection fatality rate of COVID-19. To identify these studies, we systematically performed online searches in MedRxiv, Medline, PubMed, and Google Scholar using the criterion ((*“infection fatality rate”* or *“IFR”* or *“seroprevalence”* or *“antibodies”*) and (*“COVID-19”* or *“SARS-Cov-2”*)). We also used a search tool created by the University of Zurich for searching EMBASE using the same search criterion.<sup>2</sup> We identified other studies listed in reports by government institutions including the U.K. Parliament Office.<sup>3</sup> Finally, we confirmed the coverage of our search by referring to two recent meta-analysis studies of the overall IFR for COVID-19, a recent meta-analysis of the ratio of measured seroprevalence to reported cases, and the SeroTracker global dashboard of SARS-CoV-2 seroprevalence studies.<sup>4-7</sup> Our search encompassed studies that were publicly disseminated prior to August 13. For cases in which a study was identified by the aforementioned search but age-specific seroprevalence was not found, an additional search of Twitter and Google Video was performed using additional keywords (e.g., the location of the study). Data was extracted from studies by three authors and verified prior to inclusion.

## Supplementary Appendix C: Positive predictive value of seroprevalence tests

Most studies of COVID-19 prevalence have proceeded using serological analysis to determine what fraction of the population has developed either IgG or IgM antibodies to the virus. IgM antibodies develop earlier, but decrease over time, while IgG antibodies develop later and remain in high concentrations for several months. Antibodies are tested for using several methods as summarized in Table B1. Enzyme-linked immunosorbent assays (ELISA) proceed by tagging antibody-antigen interactions with a reporter protein. Chemiluminescent immunoassays (CLA) work similarly by tagging the antigen-antibody interaction with a fluorescent protein. Lateral Flow Assays (LFA), also known as rapid diagnostic tests (RDT), produce a colored band upon antigen-antibody interaction.

Recognizing that SARS-Cov-2 is both novel and hazardous, public regulatory agencies have issued “emergency use authorizations” (EUA) to facilitate the rapid deployment of live virus and antibody tests based on the test characteristics reported by each manufacturer. Subsequent studies by independent laboratories have reassessed the characteristics of these test kits, in many cases finding markedly different results than those of the manufacturer. Such differences reflect (a) the extent to which test results may be affected by seemingly trivial differences in its implementation, and (b) the extent to which seriological properties may vary across different segments of the population. For example, a significant challenge in producing accurate tests is to distinguish COVID-19 antibodies from those associated with other coronaviruses (including the common cold). Consequently, the assessment of test characteristics may vary with seemingly innocuous factors such as the season of the year in which the blood samples were collected.

Category	Type	Description
Live Virus	Molecular Test	Targets viral nucleic acid sequence via quantitative reverse-transcription polymerase chain reaction (qRT-PCR)
	Antigen test	Targets proteins specific for the virus
Antigen (IgG / IgM)	Enzyme-linked immunosorbent assays (ELISA)	Tags antibody-antigen interactions with a reporter protein
	Chemiluminescent immunoassays (CLA)	Tags antigen-antibody interaction with a fluorescent protein
	Lateral Flow Assays (LFA); rapid diagnostic test (RDT)	Produces a colored band upon antigen antibody interactions

**Table C1: SARS-CoV-2 test methods**

The reliability of seroprevalence testing depends on three key factors: (1) the seroprevalence test's sensitivity (odds the test detects the virus in an infected person); (2) the seroprevalence test's specificity (odds the test returns a negative result for a uninfected person); and (3) the true disease prevalence in the sample. In a population where the actual prevalence is relatively low, the frequency of false-positive tests is crucial for determining the reliability of the test results.

The sensitivity and specificity of COVID-19 antibody tests should not be treated as fixed parameters that are known with a high degree of certainty, as would generally be the case for medical tests of other diseases that have been authorized via standard regulatory procedures. In particular, the confidence interval for each seroprevalence estimate should reflect the degree of uncertainty about its sensitivity and specificity as well as the conventional uncertainty that reflects the size of the sample used in producing that estimate.<sup>8,9</sup> Indeed, a recent systematic review and meta-analysis found very substantial divergences in sensitivity and specificity of COVID-19 serological tests.<sup>10</sup>

A key metric of test reliability is positive predictive value (PPV), that is, the likelihood that a positive test result is a true positive. The PPV can be evaluated as follows:

$$\text{PPV} = \frac{\text{sensitivity} \times \text{prevalence}}{\text{sensitivity} \times \text{prevalence} + (1 - \text{specificity}) \times (1 - \text{prevalence})}$$

Evidently, lower prevalence can markedly diminish the reliability of seroprevalence testing. As shown in Table C2, in a seroprevalence study of Dutch blood donors using the Wantai Total Antibody ELISA, the crude prevalence rate was found to be 2.7%.<sup>11</sup> However, that antibody test has a PPV of 42.4%, and hence the adjusted prevalence is only 0.6%, with a 95% confidence interval of 0–5.2%. In effect, *practically all of the positive tests obtained in this study might be false positives*. By contrast, a seroprevalence study of New York City found a much higher crude prevalence of 20.0% using a Wadsworth Pan-Ig test with a PPV of 94.8%.<sup>12</sup> Consequently, the adjusted prevalence for this study is *higher* than the crude prevalence, namely, 21.7% with a 95% confidence interval of 19.2–24.4%.

Test sensitivity and specificity also have a high impact on PPV. As shown in Table C3, a serological study of Santa Clara County utilized a Premier Biotech LFA test and estimated prevalence at 1.5% based on a test specificity of 99.5%.<sup>13</sup> However, a subsequent study found the specificity of that test to be only 97.2%.<sup>14</sup> That revision to the test specificity reduces its PPV in the context of the Santa Clara study to 31.1% (less than half of the PPV assumed by the authors), and hence the adjusted prevalence is not significantly greater than zero.

Location	Netherlands			New York City		
Crude Prevalence	2.7%			20%		
Test	<i>Wantai Total Antibody ELISA</i>			<i>Wadsworth Pan-Ig</i>		
		95% Confidence Bounds			95 % Confidence Bounds	
	Mean	Lower	Upper	Mean	Lower	Upper
Sensitivity	0.621	0.520	0.720	0.880	0.805	0.928
Specificity	0.977	0.950	1.000	0.988	0.973	0.995
PPV	0.424	0.224	1.000	0.948	0.882	0.979
NPV	0.989	0.986	0.992	0.971	0.952	0.982
Adjusted Prevalence	<b>0.006</b>	0.000	0.052	<b>0.217</b>	0.192	0.244

**Table C2: Impact of crude prevalence on positive predictive value**

Location	Santa Clara County					
Crude Prevalence	1.5%					
Test	<i>Premier Biotech LFA</i>					
Source	Bendavid et al.			Whitman et al.		
		95% Confidence Bounds			95 % Confidence Bounds	
	Mean	Lower	Upper	Mean	Lower	Upper
Sensitivity	0.828	0.760	0.884	0.828	0.760	0.884
Specificity	0.995	0.992	0.997	0.972	0.921	0.994
PPV	0.716	0.591	0.818	0.311	0.128	0.692
NPV	0.997	0.996	0.998	0.997	0.996	0.998
Adjusted Prevalence	0.012	0.009	0.014	0.000	0.000	0.010

**Table C3: Impact of specificity on positive predictive value**

## Supplementary Appendix D: Countries with comprehensive tracing programs

Country	Cases ( <i>thousands</i> )	Tests per confirmed case
New Zealand	1.1	1862
Australia	6.7	1054
South Korea	10.8	576
Lithuania	1.4	415
Iceland	1.8	321
Slovakia	1.4	194
Latvia	0.8	191
Austria	15.4	115
Slovenia	1.4	112
Czech Republic	7.6	104
Greece	2.6	95
Denmark	9.0	94
Estonia	1.7	70
Luxembourg	3.8	68
Israel	15.8	57
Norway	7.7	47
Poland	14.0	37
Hungary	2.8	36
Portugal	24.7	35
Belgium	49.9	32
Germany	159.1	31
Finland	4.9	31
Switzerland	29.3	27
Spain	215.2	27
Japan	14.1	25
Italy	203.6	19
Colombia	6.2	16
Canada	51.6	15
Ireland	20.3	13
Turkey	117.6	13
Chile	14.9	13
United Kingdom	167.2	10
Netherlands	38.8	8
United States	1039.9	8
Mexico	17.8	4
France	129.6	NA
Sweden	21.7	NA

*Note:* This table reports data for all OECD countries as of 30 April except Lithuania (28 April) and Poland (5 May); data on tests per confirmed case was not available for France and Sweden.<sup>15</sup> A national seroprevalence study of the Czech Republic found that infections exceeded confirmed cases by a factor of 5, suggesting that comprehensive tracing requires substantially more than 100 tests per confirmed case. By contrast, prevalence studies in Iceland and Korea indicate that the tracing programs in each of those countries were effective in identifying a high proportion of SARS-CoV-2 infections.<sup>16,17</sup>



## Supplementary Appendix E: Prevalence vs reported cases in Iceland

Age Group	Reported Cases	Estimated Infections	Confidence Interval		Ratio of Infections to Reported Cases	Confidence Interval	
			Lower	Upper		Lower	Upper
30-39	289	469	469	703	1.6	1.6	2.4
40-49	357	644	473	859	1.8	1.3	2.4
50-59	306	337	211	547	1.1	0.7	1.8
60-69	213	225	188	375	1.1	0.9	1.8
70-79	63	70	63	304	1.1	1.0	4.8
80+	25	26	13	319	1.0	0.5	12.8
All 30+	1253	1771	1415	3109	1.41	1.13	2.48

*Sources:* Cases are reported by Iceland Directorate of Health as of 14 June 2020, when Iceland had 1796 recovered cases, 10 fatalities, and 4 individuals in isolation (none hospitalized).<sup>18</sup> Estimated infections and 95% confidence intervals are taken from the prevalence study of Gudbjartsson et al. (2020), which conducted tests of a random sample of the general population on 16–31 March 2020.<sup>16</sup> As of 21 April 2020 (three weeks after the conclusion of that study), there were 1785 reported cases (98.6% of the total reported cases as of 14 June 2020).

## Supplementary Appendix F: Age-specific fatality data and source information

Location and source of fatality data	Study midpoint date in 2020	Fatality reporting date in 2020	Deaths by age group
Belgium <sup>19</sup>	April 23	May 16	0-24 yrs: 1 25-44 yrs: 30 45-64 yrs: 409 65-74 yrs: 1061 75-84 yrs: 2144 85+ yrs: 5087
England <sup>20</sup>	July 1	July 29	0-17 yrs: 11 18-24 yrs: 30 25-34 yrs: 131 35-44 yrs: 394 45-54 yrs: 1348 55-64 yrs: 3605 65-74 yrs: 7631 75+ yrs: 38629
Hungary <sup>20</sup>	May 8	June 5	0-14 yrs: 0 15-39 yrs: 4 40-64 yrs: 56 65+ yrs: 482
Italy <sup>20</sup>	July 16	August 13	0-19 yrs: 4 20-29 yrs: 16 30-49 yrs: 369 50-59 yrs: 1186 60-69 yrs: 3433 70+ yrs: 29134
Netherlands <sup>20</sup>	April 9	May 7	0-49 yrs: 40 50-59 yrs: 137 60-69 yrs: 454 70-79 yrs: 1539 80+ yrs: 2426
Portugal <sup>20</sup>	June 14	July 12	0-9 yrs: 0 10-19 yrs: 0 20-39 yrs: 4 40-59 yrs: 75 60+ yrs: 1581
Spain <sup>21</sup>	May 25	July 15	0-9 yrs: 5 10-19 yrs: 6 20-29 yrs: 35 30-39 yrs: 77 40-49 yrs: 295 50-59 yrs: 1023 60-69 yrs: 3049 70+ yrs: 24647
Sweden <sup>22</sup>	May 10	June 18	0-19 yrs: 1 20-49 yrs: 63 50-69 yrs: 504 70+ yrs: 4485
Geneva, Switzerland <sup>23</sup>	April 26	June 1	5-19 yrs: 0 20-49 yrs: 2 50-64 yrs: 16 65+ yrs: 268

**Table F1: Fatality data for European seroprevalence studies**

*Note:* Spain had a total of 29137 laboratory-confirmed COVID-19 fatalities as of 15 July 2020, including 9909 deaths in nursing homes. Age-specific fatalities outside of nursing homes are reported by Pastor-Barriuso et al. (2020).<sup>21</sup> Abellán et al. (2020) estimated that 4% of Spanish nursing home residents were aged 65-69 while the remaining 96% were aged 70+.<sup>24</sup> We used those proportions to allocate the 9909 nursing home deaths to the corresponding age groups.

Location and source of fatality data	Study midpoint date in 2020	Fatality reporting date in 2020	Deaths by age group
Atlanta <sup>25</sup>	May 1	May 31	0–17 yrs: 1 18–49 yrs: 20 50–64 yrs: 51 65+: 294
Connecticut <sup>26</sup>	April 30	May 28	0–19 yrs: 2 20–49 yrs: 75 50–59 yrs: 157 60+ yrs: 3633
Indiana <sup>27</sup>	April 27	May 25	0–39 yrs: 20 40–59 yrs: 148 60+ yrs: 1864
Louisiana <sup>28</sup>	April 5	May 6	0–18 yrs: 1 19–49 yrs: 85 50–59 yrs: 126 60+ yrs: 1053
Miami <sup>29</sup>	April 8	May 6	0–18 yrs: 0 19–49 yrs: 61 50–64 yrs: 169 65+ yrs: 1060
Minneapolis <sup>30</sup>	May 5	June 4	0–18 yrs: 0 19–49 yrs: 18 50–59 yrs: 47 60+ yrs: 928
Missouri <sup>31</sup>	April 23	May 23	0–19 yrs: 0 20–49 yrs: 18 50–59 yrs: 43 60+ yrs: 620
New York <sup>32</sup>	April 23	May 21	0–19 yrs: 12 20–39 yrs: 482 40–49 yrs: 1026 50–59 yrs: 2764 60+ yrs: 24376
Philadelphia <sup>33,34</sup>	April 19	May 17	0–18 yrs: 1 19–49 yrs: 57 50–64 yrs: 323 65+ yrs: 2639
Salt Lake City <sup>35</sup>	May 22	June 19	0–44 yrs: 4 45–64 yrs: 31 65+ yrs: 90
San Francisco <sup>36</sup>	April 25	May 25	0–18 yrs: 0 19–49 yrs: 25 50–64 yrs: 66 65+ yrs: 333
Seattle <sup>37</sup>	March 27	April 26	0–19 yrs: 0 20–39 yrs: 8 40–59 yrs: 69 60+ yrs: 700

**Table F2: Fatality data for U.S. seroprevalence studies**

Note: Some seroprevalence age brackets were adjusted (+/- 5 years) to match the age structure of that location's COVID-19 fatality report. For Pennsylvania and Utah, county-level data as of May 17 is available for total fatalities but not reported by age group; consequently, the statewide age distribution of fatalities was used to allocate county-level fatalities by age for each of those locations.

<b>Location and source of fatality data</b>	<b>Reporting date</b>	<b>Deaths by age group</b>
Australia <sup>38</sup>	June 12	0–39 yrs: 0 40–59 yrs: 3 60–69 yrs: 13 70–79 yrs: 31 80+ yrs: 55
Iceland <sup>18</sup>	June 14	0–29 yrs: 0 30–59 yrs: 1 60–69 yrs: 2 70–79 yrs: 3 80+ yrs: 4
Korea <sup>39</sup>	July 11	0–29 yrs: 0 30–39 yrs: 2 40–49 yrs: 3 50–59 yrs: 15 60–69 yrs: 41 70–79 yrs: 84 80+ yrs: 144
Lithuania <sup>40</sup>	June 21	0–39 yrs: 0 40–49 yrs: 1 50–59 yrs: 3 60–69 yrs: 12 70–79 yrs: 23 80+ yrs: 37
New Zealand <sup>41</sup>	July 9	0–59 yrs: 0 60–69 yrs: 3 70–79 yrs: 7 80+ yrs: 12

**Table F3: Fatality data for comprehensive tracing countries**

Note: Age-specific fatality data for Lithuania was published as of 01 June 2020, at which point there was a total of 70 reported fatalities; thus, the six subsequent fatalities through 22 June 2020 were assumed to have the same age distribution as the fatalities through 01 June 2020.

## Supplementary Appendix G: Metaregression methodology

To analyze IFR by age, we use meta-regression with random effects, using the *meta regress* procedure in *Stata* v16.<sup>42,43</sup> We used a random-effects procedures to allow for residual heterogeneity between studies and across age groups by assuming that these divergences are drawn from a Gaussian distribution. The procedure provides reasonable results even if the errors are not strictly normal but may be unsatisfactory if the sample includes large outliers or the distribution of groups is not unimodal. In analytical terms, this framework can be expressed as follows:

$$\log(IFR_{ij}) = \alpha + \beta * age_{ij} + \epsilon_{ij} + u_{ij}$$

where  $u_{ij} \sim N(0, \tau^2)$  and  $\epsilon_{ij} \sim N(0, \sigma_{ij}^2)$

In this specification,  $IFR_{ij}$  is the estimated IFR in study  $i$  for age group  $j$ ,  $age_{ij}$  denotes the median age of that group,  $\epsilon_{ij}$  denotes the source of idiosyncratic variations for that particular location and age group, and  $u_{ij}$  denotes the random effects that characterize any systematic deviations in outcomes across locations and age groups. Under the maintained assumption that each idiosyncratic term  $\epsilon_{ij}$  has a normal distribution, the idiosyncratic variance is  $\sigma_{ij}^2 = ((U_{ij} - L_{ij})/3.96)^2$ , where  $U_{ij}$  and  $L_{ij}$  denote the upper and lower bounds of the 95% confidence interval for that study-age group. The random effects  $u_{ij}$  are assumed to be drawn from a homogeneous distribution with zero mean and variance  $\tau^2$ . The null hypothesis of  $\tau^2 = 0$  characterizes the case in which there are no systematic deviations across studies or age groups. If that null hypothesis is rejected, then the estimated value of  $\tau^2$  encapsulates the magnitude of those systematic deviations.

Under our baseline specification, the infection fatality rate increases exponentially with age—a pattern that has been evident in prior studies of age-specific case fatality rates.<sup>44,45</sup> Consequently, our meta-regression is specified in logarithmic terms, with the slope coefficient  $\beta$  encapsulating the impact of higher age on  $\log(IFR)$ . Consequently, the null hypothesis that IFR is unrelated to age can be evaluated by testing whether the value of  $\beta$  is significantly different from zero. If that null hypothesis is rejected, then the estimated values of  $\alpha$  and  $\beta$  characterize the estimated relationship between  $\log(IFR)$  and age. Consequently, the predicted relationship between IFR and age can be expressed as follows:

$$IFR = e^{\alpha + \beta * age_{ij}}$$

The 95% confidence interval for this prediction can obtained using the delta method. In particular, let  $IFR_a$  denote the infection fatality rate for age  $a$ , and let  $\sigma_c$  denote the standard error of the meta-regression estimate of  $\log(IFR_a)$ . If  $IFR_a$  has a non-zero value, then the delta method indicates that its standard error equals  $\sigma_c / IFR_a$ , and this standard error is used to construct the confidence interval for  $IFR_a$  at each age  $a$ . Likewise, the prediction interval for  $\log(IFR_a)$  is computed using a standard error of  $\sigma_c + \tau$  that incorporates the systematic variation

in the random effects across studies and age groups, and hence the corresponding prediction interval for  $IFR_a$  is computed using a standard error of  $(\sigma_c + \tau)/IFR_a$ .

In estimating this metaregression, we exclude observations for which the lower bound of the 95% confidence interval for seroprevalence of that particular age group equals zero, and hence the upper bound of that age-specific IFR is not well defined. Similarly, we exclude observations for which the lower bound of the 95% confidence interval for seroprevalence is less than the observed COVID-19 mortality rate for that age group, since such observations would imply an upper bound for the IFR that exceeds 100%. Finally, we exclude observations for which no COVID-19 fatalities were recorded for a given age group and hence the implied value of the infection fatality rate is at its lower bound of zero and the corresponding confidence interval cannot be precisely determined.

## Supplementary Appendix H: List of excluded studies

### H.1 Studies excluded due to absence of age-specific prevalence or fatality data

Location	Description
Ariano Irpino, Italy <sup>46</sup>	This seroprevalence study collected specimens in late May from 13444 individuals (about 75% of municipality residents) and found a raw prevalence of 4.83%. No age-specific results were reported.
Austria <sup>47</sup>	Statistik Austria conducted an experimental study in which specimens were collected from 269 individuals ages 16+. The test-adjusted seroprevalence was 4.71% (CI: 1.36–7.97%). No age-specific results were reported.
Blaine County, Idaho, USA <sup>48</sup>	This study collected specimens from 972 individuals on May 4-19 and found an IgG prevalence of 22.7% (CI: 20–25.5%). The authors concluded that “the small number of county deaths ( $n=5$ ) makes estimating the infection fatality rate unreliable.” No age-specific fatality data is publicly available for this county.
Bolinas, California, USA <sup>49</sup>	University of California-San Francisco researchers collected specimens from a random sample of 1880 individuals on April 20-24. The test-adjusted seroprevalence had a 95% confidence interval of 0 to 0.3%. No age-specific results were reported.
British Columbia, Canada <sup>50</sup>	This study analyzed 885 laboratory specimens from outpatient clinics for the period May 15-27 and found only four positive cases (0.6%). No age-specific seroprevalence was reported.
Boston, Massachusetts, USA <sup>51,52</sup>	According to local media reports, researchers affiliated with the Boston Public Health Commission collected specimens from pedestrians at several locations in the Boston metropolitan area to gauge seroprevalence in these communities, but no further details had been released as of August 7.
Caldari Ortona, Italy <sup>53</sup>	This study collected specimens from 640 residents on April 18-19 and found raw prevalence of 12%. No age-specific results were reported.
Connecticut, USA <sup>54</sup>	This study analyzed specimens from a random sample of 505 adults residing in non-congregate settings. The sample design reflected the assumption of statewide prevalence of 10% (roughly similar to that of the neighboring state of New York) with the aim of obtaining prevalence estimates with precision of 2% at a confidence level of 90%. However, the study obtained a much lower estimated prevalence of 3.1% (95% CI: 1.1–5.1%). Consequently, the sample size proved to be insufficient to provide reliable age-specific results; the margin of error exceeds the estimated prevalence for all age groups reported in the study.
Czech Republic <sup>55</sup>	The Czech Ministry of Health conducted a large-scale seroprevalence survey on April 23-May 1, collecting specimens from a random sample of 22316 residents and testing for IgG antibodies using the Wantai test kit. Only 107 positive cases were identified (raw prevalence = 0.4%), and hence the test-adjusted confidence intervals include the lower bound of zero prevalence. That result is consistent with the very low number of reported cases in the Czech Republic as of early May; for example, Prague had only 1,638 reported cases for a population of 1.3 million.
Denmark <sup>56</sup>	This study analyzed specimens from a random sample of 2427 individuals in early June and identified 34 positive cases, yielding a test-adjusted prevalence of 1.2% (CI: 0.7–1.7%). Age-specific estimates were not reported as of August 12.

Faroe Islands Denmark <sup>57</sup>	This study analyzed specimens from a random sample of 1075 participants during late April and obtained 6 positive results; the test-adjusted prevalence was 0.7% (CI: 0.3–1.3%). No age-specific results were reported.
Finland <sup>58</sup>	Finland National Institute for Health and Welfare has been conducting an ongoing study of seroprevalence using random sampling of the population. Each specimen is initially screened for antibodies using a rapid test, and all specimens with positive screening results are analyzed using a microneutralization test (MNT) with confirmed specificity of 100%. As of August 8, this process screened 3155 specimens and obtained 8 positive MNT results (0.25%). No age-specific results were reported as of August 12.
Gangelt, Germany <sup>59</sup>	This study analyzed specimens from a random sample of 919 participants from the municipality of Gangelt (population 12,597) on March 31 to April 6 and obtained a test-adjusted prevalence of 15.5% (CI: 12.3–19.0%). Official government reports indicate that Gangelt had 7 COVID-19 fatalities at the time of the study but the death toll rose to 12 by late June, indicating an overall IFR of about 0.6%, similar to the IFR for Geneva. Age-specific fatalities are not reported for Gangelt.
Greece <sup>60</sup>	This study analyzed residual serum specimens from 6586 individuals collected during March and April and found 24 positive results. The test-adjusted prevalence was 0% (CI: 0–0.23%). Prevalence was reported for four age groups (0–29, 30–49, 50–69, and 70+); each of those confidence intervals included the lower limit of 0%.
Ireland <sup>61,62</sup>	Ireland Health Service conducted an antibody study using a random sample of 5,000 individuals. A media report indicated that specimens were obtained from “almost 2,500” participants and that the seroprevalence rate was “less than 5 percent” which the principal investigator described as “a little bit disappointing.” No further details had been released as of August 12.
Ischgl, Austria <sup>63</sup>	This study analyzed specimens from 184 adults in Ischgl (an Austrian municipality of 1,604 residents) and obtained 85 positive results, i.e., prevalence of 46.2%. The study reported the fraction of positive results for specific age groups (4 out of 11 adults 55–64 years, 2 out of 8 adults 65–74 years, and 1 out of 2 adults ages 75+) but did not report test-adjusted estimates or confidence intervals by age group. Ischgl had only 2 reported COVID-19 fatalities as of July 1.
Israel <sup>64</sup>	Israel Health Ministry initiated a large-scale seroprevalence study in May. Subsequent media reports indicated that initial tests of 70,000 Israelis indicated that prevalence varied significantly across regions and health organizations. No age-specific results had been released as of August 12.
Japanese Evacuees <sup>65</sup>	This study performed PCR tests on 565 Japanese citizens expatriated from Wuhan, China. There were eight positive tests, indicating a raw prevalence of 1.4%, but assessment of age-specific prevalence or IFRs is not feasible given the small sample, low prevalence, and lack of data on case outcomes.
Jersey, United Kingdom <sup>66</sup>	This study collected samples from 629 households comprising 1,062 individuals and estimated seroprevalence at 4.2% (CI 2.9 to 5.5%), indicating that about 3,300 Jersey residents have been infected. Jersey has had 30 COVID-19 fatalities (as of July 15), and hence the overall IFR is about 1% (similar to that of NYC). However, the seroprevalence sample is too small to facilitate accurate assessments of age-specific IFRs; for ages 55+, there were 258 samples and 12 positive cases,



Miami-Dade County, Florida, USA <sup>67</sup>	This study analyzed samples from 2,357 individuals in April and obtained 65 positive IgG results; an additional 275 individuals were tested in June with 4 positive results. Test-adjusted seroprevalence estimates and confidence intervals have not been published as of August 7.
New York City, New York, USA <sup>68</sup>	This study analyzed seroprevalence using specimens from four groups of patients (Cardiology, OB/GYN, Oncology, and Surgery) starting in mid-February. For the final week of the study (April 19), positive results were obtained for 47 of 243 patients; that seroprevalence estimate of 19.3% is well-aligned with the results of the New York Department of Health study. However, the sample size of this cohort is too small for assessing age-specific IFRs.
Neustadt-am-Rennsteig, Germany <sup>69</sup>	This study analyzed seroprevalence of 626 residents (71% of the population of this municipality) and estimated seroprevalence of 8.4% (52 positive cases). However, this sample size is too small for assessing age-specific IFRs.
New Orleans, Louisiana, USA <sup>70</sup>	This study analyzed seroprevalence in a random sample of 2,640 participants and obtained a seroprevalence estimate of 6.9% and an IFR of 1.6% (CI 1.5 to 1.7%). The study did not report on age-specific seroprevalence or IFRs.
Norbotten, Sweden <sup>71</sup>	This study analyzed a randomly-selected sample of 425 adults and obtained 8 positive results; the test-adjusted seroprevalence was 1.9% (CI: 0.8–3.7%). However, only 2 positive results were for ages 30-64 and 2 positive results for ages 65+, so age-specific prevalence and IFRs cannot be reliably estimated.
Norway <sup>72</sup>	Norwegian Institute of Public Health collected 900 residual serum specimens from nine laboratories from various regions of Norway and obtained test-adjusted seroprevalence of 1.0% (CI: 0.1–2.4%). The study found 4 positive results out of 372 specimens for adults ages 25–59 and 2 positive results out of 206 specimens for adults ages 60+. The authors noted that <i>“these results should be interpreted with caution”</i> due to the limited size of the sample.
Occitania, France <sup>73</sup>	This study analyzed samples from 613 individuals <i>“exposed to the virus to varying extents mimicking the general population in Occitania”</i> and found seroprevalence of 1.3% (CI: 0.6–2.6%). The study did not report any age-specific data.
Oklahoma, USA <sup>74</sup>	The Oklahoma Department of Health publishes weekly data on raw seroprevalence using samples collected from labs within the state, but its reports do not include test-adjusted estimates, confidence intervals, or age-specific results.
Oslo, Norway <sup>75</sup>	As of August 12, this ongoing study had analyzed specimens from 3250 participants in the Norwegian Mother, Father and Child Survey (MoBa) and found seroprevalence of “less than 2 percent.” No confidence intervals or age-specific results were reported.
Rhode Island, USA <sup>76</sup>	This study invited 5000 randomly-selected households, collected samples from “roughly 10 to 15 percent” who agreed to participate, and obtained seroprevalence of 2.2% (CI: 1.1–3.9%). No age-specific results have been reported as of August 1.
Riverside County, California, USA <sup>77</sup>	This study tested a randomized sample of 1,726 residents during July and found raw seroprevalence of 5.9%. The press release (issued on July 27) indicated that the results “are still being analyzed”; no test-adjusted seroprevalence results or age-specific findings have been reported as of August 1.

San Francisco Mission District, California <sup>78</sup>	This study analyzed active infections and seroprevalence of 3,953 residents in a densely populated majority Latinx neighborhood in downtown San Francisco. Positive seroprevalence in older adults was very low (22 out of 3,953) and hence too small for assessing age-specific IFRs.
San Miguel County, Colorado, USA <sup>79</sup>	The San Miguel County Health Department assessed seroprevalence in March and April using samples from 5,283 participants (66% of county residents). Raw prevalence was very low (0.53%), with only 3 confirmed positive results for adults ages 60 years and above.
Slovenia <sup>80</sup>	Researchers at the University of Ljubljana assessed seroprevalence using an IgG ELISA test for a random sample of 1,318 participants on April 20 to May 3. Test-adjusted prevalence was 0.9% (CI: 0 to 2.1%), indicating that the sample may have included only 10 infected individuals; no age-specific results were reported.
South-East England <sup>81</sup>	This study collected samples from 481 participants of the TwinsUK cohort and obtained 51 positive results (raw prevalence of 12%). No age-specific results were reported.
Stockholm, Sweden <sup>82</sup>	This study did not directly assess prevalence but produced estimates of IFR for two age groups (ages 0-69 and 70+) using a novel methodology linking live virus tests, reported cases, and mortality outcomes. The estimated IFR was 4.3% for ages 70+.
Stockholm Region, Sweden <sup>83</sup>	Stockholm County began offering antibody testing on a free walk-up basis. As of July 20, 166,431 antibody tests had been performed, of which 17.7% were positive. No demographic data or test-adjusted seroprevalence results had been reported as of August 7.
Miyagi, Osaka, and Tokyo, Japan <sup>84</sup>	This study collected samples from randomly-selected residents of three cities on June 1-7 and used two IgG test kits (Abbott and Roche); results were deemed "positive" only if confirmed by both tests. Estimated seroprevalence was 0.1% in Tokyo (2 positive results from 1,971 specimens), 0.17% in Osaka (5 positive results from 2,970 specimens), and 0.03% in Miyagi (1 positive result from 3,009 specimens). No age-specific prevalence estimates were reported.
United States <sup>85</sup>	Seroprevalence estimates are reported in the U.S. CDC's weekly COVID-19 surveillance summary using data collected by 85 state and local public health laboratories. These reports include age-specific seroprevalence but no details regarding sample selection, test characteristics, or confidence intervals and hence could not be used in our metaregression.
Utsunomiya, Japan <sup>86</sup>	This study tested a random sample of 742 participants and found 3 confirmed positive results among 463 adults ages 18 to 65 years; the test-adjusted prevalence for that age group was 0.65% (CI: 0.13% to 1.8%). No positive results were obtained for the sample of 181 adults ages 65+ years.
Virginia, USA <sup>87</sup>	Virginia Department of Health collected specimens from a random sample of 3113 participants ages 16+ during early June and estimated prevalence of 2.4%. No confidence intervals or age-specific results had been released as of August 12.
Vo, Italy <sup>88</sup>	Vo' is a municipality of 3,300 people, nearly all of whom (87%) participated in an infection survey in late February. However, there were only 54 infections among people ages 50+, so assessing age-specific IFRs is not feasible.
Washoe County, Nevada, USA <sup>89</sup>	This study collected samples from 234 individuals on June 9-10 and obtained 5 positive IgG results. No age-specific results were reported.

Winston-Salem, North Carolina, USA <sup>90</sup>	This ongoing study has been collecting specimens from a representative sample of area residents since mid-April, and raw prevalence was characterized as “ <i>about 10%</i> .” On July 28 the researchers issued an update indicating that the antibody test was not sufficiently sensitive and that a new test would be deployed henceforth.
--	---

## H.2: Studies excluded due to accelerating outbreak

Location	Date	Cumulative fatalities in thousands		Change (%)
		Study midpoint	4 weeks later	
Los Angeles, California, USA <sup>91</sup>	April 10-11	0.265	1.468	454
New York City, New York, USA <sup>92</sup>	March 23-April 1	1.066	14.261	1238

## H.3 Studies excluded due to non-representative samples

### H.3.1 Active recruitment of participants

Location	Description
Luxembourg <sup>93</sup>	Of the 35 participants who tested positive, 19 had previously interacted with a person who was known to be infected or had a prior test for SARS-CoV-2.
Boise, Idaho <sup>94</sup>	This study was promoted during a “Crush the Curve” publicity campaign and required participants to sign up for a test.
Santa Clara, California, USA <sup>13</sup>	Participants were recruited via social media and needed to drive to the testing site. Stanford Medicine subsequently released a statement indicating that the study was under review due to concerns about potential biases. <sup>95</sup>
Frankfurt, Germany <sup>96</sup>	This study was conducted at a industrial worksite. Among the 5 seropositive participants, 3 had prior positive tests or direct contact with a known positive case.

### H.3.2 Studies of blood donors

Location	Description
Apulia, Italy <sup>97</sup>	This study assessed specimens from a sample of 904 healthy blood donors at a transfusion center in southeastern Italy and obtained 9 positive results (0.99%).
Denmark <sup>98</sup>	This study assessed specimens from a sample of 20640 Danish blood donors and calculated a test-adjusted prevalence of 1.9% (CI:0.8–2.3). Unfortunately, the antibody test used in this study was subsequently identified as unreliable, and the Danish government returned all remaining test kits to the manufacturer. <sup>99</sup>
England <sup>100</sup>	Public Health England has conducted ongoing surveillance of seroprevalence using specimens from healthy adult blood donors. For example, in 7694 samples tested during May (weeks 18-21), the test-adjusted prevalence was 8.5% (CI: 6.9–10%).
Germany <sup>101</sup>	This study assessed residue sera from 3186 regular blood donors collected during March 9–June 3 and obtained 29 positive results (raw prevalence 0.9%). The authors stated: <i>“It should be emphasized that the preselection of blood donors as a study cohort is accompanied by limitations regarding representation of population.”</i>
Lombardy, Italy <sup>102</sup>	This study assessed specimens from 390 blood donors residing in the Lodi red zone collected on April 6 and found a raw seroprevalence rate of 23%.
Milan, Italy <sup>103</sup>	This study assessed specimens from a random sample of 789 blood donors over the period from February 24 (at the start of the outbreak) to April 8.
Netherlands <sup>11</sup>	This study assessed specimens from 7361 adult blood donors collected on April 1-15 and found seroprevalence of 2.7%.
Rhode Island, USA <sup>104</sup>	This study assessed specimens from 2008 blood donors collected during April 27–May 11 and found seroprevalence of 0.6%.
Scotland <sup>105</sup>	This study assessed specimens from 3500 blood donors collected between March 17 and May 19. The authors noted that the resulting estimates of seroprevalence <i>“are complicated by non-uniform sampling...based on the locations where weekly donations took place...[and] further confounded by the absence of samples from individuals below age 18 and individuals over age 75.”</i>
San Francisco, California, USA <sup>106</sup>	This study assessed specimens from 1000 blood donors that were collected during March and found one positive result (raw prevalence 0.1%).

### H.3.3 Studies of hospitals and urgent care clinics

Location	Description
Brooklyn, New York, USA <sup>107</sup>	This study used samples from an outpatient clinic and yielded a much higher infection rate than other seroprevalence studies of the New York metropolitan area.
Kobe, Japan <sup>108</sup>	This study tested for IgG antibodies in 1,000 specimens from an outpatient clinic and found 33 positive cases. However, the study did not screen out samples from patients who were seeking treatment for COVID-related symptoms. Moreover, the study reported raw prevalence and confidence interval but did not report statistics adjusted for test characteristics. The manufacturer (ADS Biotec / Kurabo Japan) has indicated that this test has specificity of 100%, based on a sample of 14 pre-COVID specimens, but that specificity has not been evaluated by any independent study. If the true specificity is 98%, then the adjusted prevalence would not be significant. The authors concluded by noting the selection bias and recommended that <i>“further serological studies targeting randomly selected people in Kobe City could clarify this potential limitation.”</i>
Tokyo, Japan <sup>109,110</sup>	The authors of this study specifically cautioned against interpreting their results as representative of the general population. In particular, the sample of 1,071 participants included 175 healthcare workers, 332 individuals who had experienced a fever in the past four months, 45 individuals who had previously taken a PCR test, and 9 people living with a COVID-positive cohabitant. The study obtained a raw infection rate of 3·8%, but the rate is only 0·8% if those subgroups are excluded.
Zurich, Switzerland <sup>111</sup>	This study analyzed two distinct set of samples: (i) blood donors and (ii) hospital patients. Nearly all blood donors were ages 20 to 55, so that sample is not useful for assessing age-specific IFRs for older adults. The sample of hospital patients was not screened to eliminate cases directly related to COVID-19, so that sample may not be representative of the broader population. Moreover, inhabitants of the city of Zurich constituted a relatively large fraction of seropositive results compared to residents from the remainder of the canton of Zurich (which is predominantly rural). The study computes an overall IFR of 0·5%, similar to that of Geneva.

### H.3.4 Other sample selection issues

Location	Description
Oisie, France <sup>112</sup>	This sample of 1,340 participants included elementary school teachers, pupils, and their families. Only two individuals in the sample were ages 65 years and above.
Saxony, Germany <sup>113</sup>	This study analyzed specimen samples from students and teachers at thirteen secondary schools in eastern Saxony and found very low seroprevalence (0·6%).

#### H.4 Exclusion of observations with statistically insignificant seroprevalence

Location	Age Group	Prevalence (%)	95% Confidence Interval (%)	
			Lower Bound	Upper Bound
Atlanta, Georgia, USA	0–17	0	0	1·0
	65+	0·7	0·1	4·5
Connecticut, USA	0–18	0·8	0	2·9
Louisiana, USA	0–18	2·8	0	11·5
Miami, Florida, USA	0–18	2·4	0	7·8
Minneapolis, Minnesota, USA	0–18	5·8	0	14·3
	50–59	0·7	0	2·8
	60+	1·0	0	3·2
Missouri, USA	0–18	1·4	0	4·1
Philadelphia, Pennsylvania, USA	0–18	2·2	0	6·9
	50–64	0·8	0	2·8
	65+	1·6	0·3	3·5
Salt Lake City, Utah, USA	65+	0·6	0	1·4
San Francisco, California, USA	0–18	1·7	0	7·7
	19–49	1·1	0	2·6
	50–64	0·7	0	2·4
Seattle, Washington, USA	0–18	0·7	0	2·5

*Note: This table shows observations for which either (a) the lower bound of the 95% confidence interval equals zero, and hence the upper bound of the IFR is not well defined; or (b) the lower bound of the 95% confidence interval is less than the observed COVID-19 mortality rate for that age group, implying an upper bound for the IFR that exceeds 100%.*

**H.5 Exclusion of observations with no observed fatalities**

Location	Age Group	Population (millions)	Infections (thousands)	
			Estimate	95% confidence interval
Geneva	5–19	0.796	7.300	4.300–11.200
Hungary	0–14	1.391	7.795	3.758–11.971
Portugal	0–9	0.841	17.663	6.729–45.418
	10–19	1.015	21.318	8.121–55.834
Australia	0–39	13.533	2.800	4.200–12.600
Iceland	0–29	0.136	0.554	0.407–0.608
Korea	0–29	15.623	15.180	6.939–21.685
Lithuania	0–39	1.198	1.845	0.843–2.635
New Zealand	0–59	3.751	3.726	1.876–5.627

*Note: This table shows observations for relatively young age groups in locations where no COVID-19 fatalities were recorded for that age group and hence the implied value of the infection fatality rate is at its lower bound of zero and its confidence interval cannot be precisely determined.*

**Supplementary Appendix I: Assessment of risk of bias for included studies**





## Supplementary Appendix J: Assessment of Publication Bias

(1) Regression-based Egger test for small-study effects

Random-effects model estimated using REML

$H_0: \beta = 0$ ; no small-study effects

$\beta = -1.14$ ,  $SE(\beta) = 18.826$ ,

$z = -0.06$ ,  $Prob > |z| = 0.9517$

(2) Nonparametric trim-and-fill analysis of publication bias

Linear estimator, imputing on the right

Number of studies = 98

Model: Random-effects


Method: REML

Observed = 98, Imputed = 0

Effect Size and 95% Confidence Interval

Observed: 0.023 (-0.108, 0.154)


Observed + Imputed: 0.023 (-0.108, 0.154)



## Supplementary Appendix K: Out-of-sample analysis of metaregression results

Study	Description
Castiglione d'Adda, Italy <sup>114</sup>	This study assessed seroprevalence in a random sample of 509 residents of the municipality of Castiglione d'Adda, the location of the first COVID-related fatality in Italy. Specimens were collected on May 18–25. Seroprevalence was estimated at 22·6% (CI: 17·2–29·1%). This study is included in our meta-analysis but not in our metaregression because this municipality is covered by a nationwide seroprevalence study of Italy. <sup>115</sup>
Diamond Princess Cruise Ship <sup>116</sup>	This ship was carrying 3,711 passengers and crew; its demographic composition was not necessarily representative of any specific geographical location. RT-PCR tests indicated that 619 individuals had been infected prior to the ship's disembarkation on March 7, and 14 individuals subsequently died due to COVID-related causes. The IFR was 0·5% for ages 60-69, 2·9% for ages 70-79, and 7·9% for ages 80+, broadly consistent with the metaregression results of this study.
U.K. Biobank <sup>117</sup>	This study assessed seroprevalence using specimens collected from a demographically balanced panel of 17,776 participants on May 27 to July 6. Our metaregression includes a much larger seroprevalence study of the English population. <sup>118</sup> Consequently, this study is included in our meta-analysis but not in our metaregression to avoid pitfalls of nested or overlapping samples.
U.K. Office of National Statistics <sup>119</sup>	The U.K. Office for National Statistics (ONS) regularly reports estimates of seroprevalence from specimens provided for routine testing using an IgG ELISA test conducted by research staff at the University of Oxford. On August 18 the ONS reported age-specific results for the cumulative sample of 4840 specimens received from 26 April to 26 July and indicated that these results were broadly consistent with the findings of the UK REACT-2 study (which utilized a much larger sample).
Utah, USA <sup>92</sup>	This study analyzed commercial lab specimens from 1132 individuals collected during April 20–May 3. This study is not included in our meta-analysis because a subsequent study analyzed a much larger randomized sample of 6527 residents of the Salt Lake City metropolitan area during May 4–June 10. <sup>120</sup> As of May, that metro area accounted for nearly 90% of COVID-related fatalities in Utah.

**Table K1: List of studies used in out-of-sample analysis**



**Table K2: Out-of-sample analysis of metaregression results**

**Supplementary Appendix L: Infection fatality rate for seasonal influenza**

The U.S. Center for Disease Control and Prevention provides annual estimates of the U.S. impact of seasonal influenza based on reporting from state and local public health laboratories and other sources. For the winter season of 2018-2019, its preliminary estimate is 35.5 million symptomatic cases and 34 thousand fatalities.<sup>121</sup> A systematic review and meta-analysis of 55 studies found that 25.4% to 61.8% of influenza infections were subclinical, i.e., did not meet the criteria for acute respiratory illness.<sup>122</sup> Using the midpoint of that interval, we estimate that the total U.S. incidence of seasonal influenza during winter 2018-19 was about 63 million and hence that the infection fatality rate was about 0.05%.

## Supplementary Appendix M: U.S. scenario analysis

Scenario	Infection Rate by Age ( <i>percent</i> )				Deaths ( <i>thousands</i> )	IFR ( <i>percent</i> )
	All	0-49	50-64	65+		
<i>Baseline (July 2020)</i>	8.0	9.0	7.1	6.0	175	0.6
<b>Scenario #1:</b> <i>current pattern of age-specific prevalence</i>	20	23	16	14	375	0.6
<b>Scenario #2:</b> <i>uniform prevalence</i>	20	20	20	20	525	0.8
<b>Scenario #3:</b> <i>protection of vulnerable age groups</i>	20	26	10	6	235	0.3

*Note:* The baseline scenario is constructed using age-specific prevalence as measured by U.S. public health laboratories during the second half of July 2020.<sup>85</sup> The fatalities in this baseline scenario are projected using the age-specific IFR estimates from the metaregression, and the U.S. IFR of 0.6% is obtained by aggregating infections and fatalities across age groups. All three alternative scenarios have the same average infection rate of 20% but with a distinct pattern of age-specific prevalence, and the metaregression IFR estimates are used to project fatalities and the population IFR for each scenario.

### Supplementary Appendix N: Comparison of age-specific IFRs and CFRs

Age (years)	IFR (%)	CFR (%)	Ratio
0-29	0.003	0.3	100
30-39	0.034	0.5	14.7
40-49	0.12	1.1	9.2
50-59	0.40	3.0	7.5
60-69	1.34	9.5	7.1
70-79	4.49	22.8	5.1
80+	15.0	29.6	2.0

*Note:* This table compares the estimated age-specific IFRs from our metaregression with the age-specific case fatality rates (CFRs) of Bonanad et al. (2020).<sup>44</sup>

## Supplementary Appendix O: Comorbidities and Demographic Factors

While age and fatality risk are closely related, differences in the age structure of the population and age-specific infection rates surely cannot explain all deviations in IFR across regions and populations. Consequently, the role of co-morbidities and other demographic and socioeconomic factors merits further research that carefully distinguishes between infection risk and IFR.

A recent U.K. study has shown that COVID-19 mortality outcomes are strongly linked to comorbidities such as chronic pulmonary disease, diabetes, and obesity.<sup>123</sup> However, that study specifically warns against drawing causal conclusions from those findings, which may reflect a higher incidence of COVID-19 rather than a higher IFR for individuals with those comorbidities. Indeed, as shown in Table O1, a study of hospitalized U.K. COVID-19 patients found that patient age was far more important than any specific comorbidity in determining mortality risk.<sup>45</sup> For example, the COVID-19 fatality risk for an obese 40-year-old hospital patient was found to be moderately higher than for a non-obese individual of the same cohort but only one-tenth the fatality risk for a non-obese 75-year-old hospital patient.

The high prevalence of comorbidities among COVID-19 patients has been well documented but not compared systematically to the prevalence of such comorbidities in the general population. For example, one recent study of hospitalized COVID-19 patients in New York City (NYC) reported that 94% of those patients had at least one chronic health condition.<sup>124</sup> However, as shown in Table O2, that finding is not particularly surprising given the prevalence of comorbidities among middle-aged and elderly NYC residents. For example, nearly 30% of older NYC adults (ages 60+) are diabetic, while 23% have cardiovascular disease (including hypertension), and 8% have chronic pulmonary diseases—practically identical to the incidence of those comorbidities in the sample of hospitalized COVID-19 patients. Indeed, obesity was the *only* comorbidity that was much more prevalent among hospitalized COVID-19 patients than in the general population of older NYC adults. Nonetheless, obesity is also much more prevalent among lower-income groups who are more likely to live in high-density neighborhoods and work in high-exposure jobs, and hence such data clearly cannot be used to distinguish prevalence vs. severity of COVID-19.

Our meta-analysis has not directly considered the extent to which IFRs may vary with other demographic factors, including race and ethnicity. Fortunately, valuable insights can be garnered from other recent studies. In particular, one recent seroprevalence study of residents of two urban locations in Louisiana found no significant difference in IFRs between whites and Blacks.<sup>70</sup>

Nonetheless, the incidence of COVID-19 mortality among people of color is extraordinarily high due to markedly different infection rates that reflect systematic racial and ethnic disparities in housing and employment. For example, a recent infection study of a San Francisco neighborhood found that 80% of positive cases were Latinx – far higher than the proportion of Latinx residents in that neighborhood.<sup>78</sup> That study concluded as follows: “*Risk factors for recent infection were Latinx ethnicity, inability to shelter-in-place and maintain income, frontline service work, unemployment, and household income less than \$50,000 per year.*”

Other researchers have reached similar conclusions, attributing elevated infection rates among Blacks and Hispanics to dense housing of multi-generational families, increased employment in high-contact service jobs, high incidence of chronic health conditions, and lower quality of health care.<sup>125</sup>

In summary, while our meta-analysis has investigated the effects of age on IFR for COVID-19, further research needs to be done on how infection and fatality rates for this disease are affected by comorbidities as well as demographic and socioeconomic factors.

Age	Hazard Ratio	Comorbidity	Hazard Ratio
20 to 49	1	Diabetes	1.1
50 to 59	2.7	Malignant Cancer	1.1
60 to 69	5.5	Chronic Cardiac Disease	1.2
70 to 79	9.8	Chronic Pulmonary Disease	1.2
80+	13.5	Chronic Kidney Disease	1.3
		Obesity	1.3
		Liver Disease	1.5

**Table O1: Fatality hazard ratios for hospitalized U.K. COVID-19 patients**

*Source: Doherty et al. (2020), Figure 5.*



<b>Comorbidity</b>	<b>NYC Hospitalized COVID Patients</b>	<b>NYC Population (Ages 50+)</b>	<b>Difference</b>
<b>Cancer</b>	5.6%	6.3%	-0.7%
<b>Cardiovascular Disease</b>			
Hypertension	53.1%	49.2%	3.9%
Coronary artery disease	10.4%	10.5%	-0.1%
Congestive heart failure	6.5%	6.9%	-0.4%
<b>Chronic Respiratory Disease</b>			
Asthma	8.4%	8.6%	-0.2%
Chronic obstructive pulmonary disease	5.0%	7.7%	-2.7%
Obstructive sleep apnea	2.7%	2.8%	-0.1%
<b>Immunosuppression</b>			
HIV	0.8%	2.7%	-2.0%
History of solid organ transplant	1.0%	NA	NA
<b>Kidney Disease</b>			
Chronic	4.7%	13.1%	-8.4%
End-Stage	3.3%	0.6%	2.6%
<b>Liver Disease</b>			
Cirrhosis	0.3%	0.9%	-0.6%
Hepatitis B	0.1%	0.5%	-0.3%
Hepatitis C	0.1%	0.1%	0.0%
<b>Metabolic Disease</b>			
Obesity (BMI $\geq$ 30)	41.7%	26.9%	14.8%
Diabetes	31.7%	27.6%	4.1%
<b>Ever Smoked</b>	15.6%	43.8%	-28.2%

**Table O2: Comorbidity prevalence in New York City (NYC) hospitalized COVID-19 patients vs. general population**

*Note:* The following sources were used to gauge the prevalence of comorbidities among NYC residents ages 50 years and above. *Asthma:* U.S. Center for Disease Control & Prevention (2018). *Cancer:* New York State Cancer Registry (2016). *Cardiovascular Diseases:* New York Department of Health (2020). *Diabetes:* New York State Comptroller (2015). *HIV:* New York City Department of Health (2018). *Kidney Disease:* IPRO End-Stage Renal Disease Network of New York (2014). *Liver Disease:* Moon et al. (2019) and Must et al. (1999). *Chronic Pulmonary Disease:* New York Department of Health (2019). *Obesity:* New York City Department of Health (2019).

## **Supplementary Appendix P: Excess mortality**

In some locations, reported deaths may not fully capture all fatalities resulting from COVID-19 infections, especially when a large fraction of such deaths occur outside of medical institutions. In the absence of accurate COVID-19 death counts, *excess mortality* can be computed by comparing the number of deaths for a given time period in 2020 to the average number of deaths over the comparable time period in prior calendar years, e.g., 2015 to 2019. This approach has been used to conduct systematic analysis of excess mortality in European countries.<sup>126</sup> For example, the Belgian study used in our metaregression computed age-specific IFRs using seroprevalence findings in conjunction with data on excess mortality in Belgium; the authors noted that Belgian excess mortality over the period from March to May coincided almost exactly with Belgium's tally of reported COVID-19 cases.<sup>19</sup>

## References for Supplementary Appendices

- 1 Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ* 2009; **339**: b2535.
- 2 University of Zurich Zika Open Access Project. Living Evidence on COVID-19. 2020. [https://zika.ispm.unibe.ch/assets/data/pub/search\\_beta/](https://zika.ispm.unibe.ch/assets/data/pub/search_beta/) (accessed August 12 2020).
- 3 United Kingdom Parliament Office. Antibody Tests for COVID-19. 2020.
- 4 Byambasuren O, Dobler CC, Bell K, et al. Estimating the seroprevalence of SARS-CoV-2 infections: systematic review. 2020.
- 5 Ioannidis J. The infection fatality rate of COVID-19 inferred from seroprevalence data. 2020.
- 6 Meyerowitz-Katz G, Merone L. A systematic review and meta-analysis of published research data on COVID-19 infection-fatality rates. 2020.
- 7 Arora RK, Joseph A, Van Wyk J, et al. SeroTracker: a global SARS-CoV-2 seroprevalence dashboard. *The Lancet Infectious Diseases*.
- 8 Larremore DB, Fosdick BK, Bubar KM, et al. Estimating SARS-CoV-2 seroprevalence and epidemiological parameters with uncertainty from serological surveys. 2020.
- 9 Manski CF, Molinari F. Estimating the COVID-19 infection rate: Anatomy of an inference problem. *J Econom* 2020.
- 10 Lisboa Bastos M, Tavaziva G, Abidi SK, et al. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. *BMJ* 2020; **370**: m2516.
- 11 Slot E, Hogema BM, Reusken CBEM, et al. Herd immunity is not a realistic exit strategy during a COVID-19 outbreak. 2020.
- 12 Rosenberg ES, Tesoriero JM, Rosenthal EM, et al. Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York. *annals of epidemiology* 2020.
- 13 Bendavid E, Mulaney B, Sood N, et al. COVID-19 Antibody Seroprevalence in Santa Clara County, California. 2020.
- 14 Whitman JD, Hiatt J, Mowery CT, et al. Test performance evaluation of SARS-CoV-2 serological assays. *medRxiv* 2020.
- 15 Our World in Data. Coronavirus (COVID-19) testing: tests per confirmed case. 2020. <https://ourworldindata.org/coronavirus-testing#tests-per-confirmed-case> (accessed August 18).
- 16 Gudbjartsson DF, Helgason A, Jonsson H, et al. Spread of SARS-CoV-2 in the Icelandic Population. *N Engl J Med* 2020; **382**(24): 2302-15.
- 17 Korea Center for Disease Control. Updates on COVID-19 in Korea as of July 9. 2020.
- 18 Iceland Directorate of Health. COVID-19 in Iceland - Statistics 28 Feb to 14 June 2020. 2020.
- 19 Molenberghs G, Faes C, Aerts J, et al. Belgian Covid-19 Mortality, Excess Deaths, Number of Deaths per Million, and Infection Fatality Rates (8 March - 9 May 2020). 2020.
- 20 European Centre for Disease Prevention and Control. Clinical characteristics of COVID-19. 2020.
- 21 Pastor-Barriuso R, Perez-Gomez B, Hernan MA, et al. SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study. *medRxiv* 2020: 2020.08.06.20169722.
- 22 Sweden Public Health Authority. COVID-19 Report for Week 24 - COVID-19 veckorapport vecka 24. 2020.
- 23 Perez-Saez J, Lauer SA, Kaiser L, et al. Serology-informed estimates of SARS-CoV-2 infection fatality risk in Geneva, Switzerland. *The Lancet Infectious Diseases*.
- 24 Abellán A, Aceituno P, Fernández I, Ramiro D, Pujol R. Una estimación de la población que vive en residencias de mayores. *Envejecimiento en red* 2020.
- 25 Georgia Department of Public Health. COVID-19 Daily Status Report 2020.
- 26 Connecticut Department of Health & Human Services. COVID-19 cases and deaths by age group. 2020.
- 27 Indiana State Department of Public Health. Indiana COVID-19 data report – demographic distributions. 2020.

- 28 Louisiana Department of Health. Louisiana coronavirus (COVID-19) information – cases/deaths by age group. 2020.
- 29 Florida Department of Health. Florida COVID-19 case line data. 2020.
- 30 Minnesota Department of Health. COVID-19 newly reported deaths detail - age group data table including age group of deaths. 2020.
- 31 Missouri Department of Health & Senior Services. Missouri COVID-19 dashboard. 2020.
- 32 New York Department of Health. COVID-19 Tracker – Fatalities by Age Group. 2020.
- 33 Pennsylvania Department of Health. COVID-19 death data for Pennsylvania. 2020.
- 34 Pennsylvania Department of Health. Weekly report for deaths attributed to COVID-19. 2020.
- 35 Utah Department of Health. COVID-19 surveillance. 2020.
- 36 California Department of Public Health. Data dashboards - COVID-19 in the state. 2020.
- 37 Washington Department of Health. Novel coronavirus outbreak (COVID-19) cases and deaths by week of illness onset, county, and age. 2020.
- 38 Australia Department of Health. Coronavirus (COVID-19) current situation and case numbers. 2020.
- 39 Korea Center for Disease Control. Weekly Report on the COVID-19 Situation in the Republic of Korea. 2020.
- 40 Lithuania Central Registry. Koronaviruso (COVID-19) Lietuvoje statistika. 2020.
- 41 New Zealand Ministry of Health. COVID-19 Current Cases. 2020.
- 42 Harbord RM, Higgins JPT. Meta-regression in Stata. *Stata Journal* 2008; **8**(4): 493-519.
- 43 Higgins JPT, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. *J R Stat Soc Ser A Stat Soc* 2009; **172**(1): 137-59.
- 44 Bonanad C, Garcia-Blas S, Tarazona-Santabalbina F, et al. The Effect of Age on Mortality in Patients With COVID-19: A Meta-Analysis With 611,583 Subjects. *J Am Med Dir Assoc* 2020; **21**(7): 915-8.
- 45 Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. *BMJ* 2020; **369**: m1985.
- 46 Giustizia News. Coronavirus, l'incubo senza fine di Ariano Irpino: 60 positivi al tampone dopo i test sierologici. May 28.
- 47 Austria Statistik. COVID-19 prevalence study: a maximum of 0.15% of the population in Austria infected with SARS-CoV-2. 2020.
- 48 McLaughlin CC, Doll MK, Morrison KT, et al. High Community SARS-CoV-2 Antibody Seroprevalence in a Ski Resort Community, Blaine County, Idaho, US. Preliminary Results. *medRxiv* 2020.
- 49 University of California-San Francisco. Town of Bolinas antibody tests find minimal history of infection. 2020.
- 50 Skowronski DM, Sekirov I, Sabaiduc S, et al. Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020. 2020.
- 51 Saltzman J. Nearly a third of 200 blood samples taken in Chelsea show exposure to coronavirus. *Boston Globe*. 2020 4/17/2020.
- 52 Saltzman J. Study: 1 out of 10 residents in 4 neighborhoods unwittingly had coronavirus. *Boston Globe*. 2020 May 15.
- 53 Micolitti A. Caldari Ortona: 12% cittadini sottoposti a test sierologici positivi con anticorpi al Covid 19. *Rete8*. 2020 June 3.
- 54 Mahajan S, Srinivasan R, Redlich CA, et al. Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study. *medRxiv* 2020: 2020.08.04.20168203.
- 55 Czech Ministry of Health. Collective Immunity Study SARS-CoV-2: Czech Prevalence. 2020.

- 56 Denmark State Blood Institute. Notat: Nye foreløbige resultater fra den repræsentative seroprævalensundersøgelse af COVID-19. 2020.
- 57 Petersen MS, Strøm M, Christiansen DH, et al. Seroprevalence of SARS-CoV-2–Specific Antibodies, Faroe Islands. *emerging infectious diseases* 2020; **26**(11).
- 58 Finland National Institute for Health and Welfare. Weekly report of THL serological population study of the coronavirus epidemic. 2020.
- 59 Streeck H, Schulte B, Kuemmerer B, et al. Infection fatality rate of SARS-CoV-2 infection in a German community with a super-spreading event. 2020.
- 60 Bogogiannidou Z, Vontas A, Dadouli K, et al. Repeated leftover serosurvey of SARS-CoV-2 IgG antibodies, Greece, March and April 2020. *Eurosurveillance* 2020; **25**(31): 2001369.
- 61 Ireland Health Service Executive. SCOPI: COVID-19 antibody research project. 2020.
- 62 Carswell S. Coronavirus: Ireland has 'no significant' herd immunity, study shows. The Irish Times. 2020 July 20.
- 63 von Laer D. U.S. National Institutes of Health COVID-19 lecture: high seroprevalence, drastic decline of incidence, and low infection fatality rate of SARS-CoV-2 infections in children and adults in the ski resort Ischgl, Austria. 2020.
- 64 Times of Israel Staff. Coronavirus : Israël est encore loin de l'immunité de groupe. Times of Israel. 2020 July 23.
- 65 Nishiura H, Kobayashi T, Yang Y, et al. The Rate of Underascertainment of Novel Coronavirus (2019-nCoV) Infection: Estimation Using Japanese Passengers Data on Evacuation Flights. *J Clin Med* 2020; **9**(2).
- 66 Jersey Health & Community Services. Prevalence of Antibodies – Community Survey Round 2. 2020.
- 67 University of Miami. SPARK-C: understanding the burden of COVID-19 in Miami-Dade County through rapid serological testing of a representative random sample. 2020.
- 68 Stadlbauer D, Tan J, Jiang K, et al. Seroconversion of a city: Longitudinal monitoring of SARS-CoV-2 seroprevalence in New York City. *medRxiv* 2020: 2020.06.28.20142190.
- 69 Weis S, Scherag A, Baier M, et al. Seroprevalence of SARS-CoV-2 antibodies in an entirely PCR-sampled and quarantined community after a COVID-19 outbreak - the CoNAN study. 2020.
- 70 Feehan AK, Fort D, Garcia-Diaz J, et al. Seroprevalence of SARS-CoV-2 and Infection Fatality Ratio, Orleans and Jefferson Parishes, Louisiana, USA, May 2020. *Emerg Infect Dis* 2020; **26**(11).
- 71 Norrbotten Region. Forekomst av antikroppar mot covid-19 - Norrbottens befolkning maj 2020. 2020.
- 72 Health NloP. Seroprevalence of SARS-CoV-2 in the Norwegian population measured in residual sera collected in April/May 2020 and August 2019. 2020.
- 73 Dimeglio C, Loubes J-M, Miedougé M, Herin F, Soulat J-M, Izopet J. The real seroprevalence of SARS-CoV-2 in France and its consequences for virus dynamics. Research Square; 2020.
- 74 Oklahoma State Department of Health. Weekly Epidemiology and Surveillance Report. 2020.
- 75 Norway Public Health Institute. Truleg berre ein liten andel av befolkninga som har vore smitta av koronavirus. 2020.
- 76 Rhode Island Department of Health. COVID-19 serology testing brief. 2020.
- 77 Riverside County Joint Information Center. Antibody study shows coronavirus spread wider in Riverside County. 2020.
- 78 Chamie G, Marquez C, Crawford E, et al. SARS-CoV-2 Community Transmission During Shelter-in-Place in San Francisco. 2020.
- 79 San Miguel County Department of Health & Environment. IgG Antibody Tests: Statistics and Demographics. 2020.
- 80 Slovenia Government Communication Office. First study carried out on herd immunity of the population in the whole territory of Slovenia. 2020.

- 81 Wells PM, Doores KM, Couvreur S, et al. Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England. 2020.
- 82 Sweden Public Health Authority. The Infection Fatality Rate of COVID-19 in Stockholm – Technical Report. 2020.
- 83 Stockholm Region. Lägesrapport om arbetet med det nya coronaviruset. 2020.
- 84 Japan Ministry of Health Labour and Welfare. Updates on COVID-19 in Japan. 2020.
- 85 U.S. Center for Disease Control and Prevention. COVIDView weekly report - U.S. virologic surveillance by public health laboratories. 2020.
- 86 Nawa N, Kuramochi J, Sonoda S, et al. Seroprevalence of SARS-CoV-2 IgG Antibodies in Utsunomiya City, Greater Tokyo, after first pandemic in 2020 (U-CORONA): a household- and population-based study. 2020.
- 87 Virginia Office of the Governor. Governor Northam announces launch of pediatric coronavirus serology study; interim adult serology study findings show an estimated 2.4% of adult Virginians have COVID-19 antibodies. 2020.
- 88 Lavezzo E, Franchin E, Ciavarella C, et al. Suppression of COVID-19 outbreak in the municipality of Vo, Italy. 2020.
- 89 Washoe County Health District. Seroprevalence of SARS-CoV-2 Specific Antibodies Among Adults in Washoe County, Nevada on June 9-10, 2020. 2020.
- 90 Wake Forest Baptist Health. COVID-19 community research partnership study results and data. 2020.
- 91 Sood N, Simon P, Ebner P, et al. Seroprevalence of SARS-CoV-2-Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020. *JAMA* 2020.
- 92 Havers FP, Reed C, Lim T, et al. Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020. *JAMA Intern Med* 2020.
- 93 Snoeck CJ, Vaillant M, Abdelrahman T, et al. Prevalence of SARS-CoV-2 infection in the Luxembourgish population: the CON-VINCE study. 2020.
- 94 Bryan A, Pepper G, Wener MH, et al. Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho. *J Clin Microbiol* 2020; **58**(8).
- 95 Kekatos M. Stanford University is investigating its own researchers over claims their antibody study was politically motivated and 'tipped the scale' to make COVID-19 seem less lethal. Daily Mail. 2020 May 26.
- 96 Kraehling V, Kern M, Halwe S, et al. Epidemiological study to detect active SARS-CoV-2 infections and seropositive persons in a selected cohort of employees in the Frankfurt am Main metropolitan area. 2020.
- 97 Fiore J, Centra M, de Carlo A, et al. Far away from herd immunity to SARS-CoV-2: results from a survey in healthy blood donors in southeastern Italy. 2020.
- 98 Erikstrup C, Hother CE, Pedersen OBV, et al. Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors. *clinical infectious diseases* 2020.
- 99 Reuters Health News. Denmark to send back inaccurate antibody tests from China's Livzon. 2020 May 20.
- 100 Public Health England. Sero-Surveillance of COVID-19: Week 22. 2020.
- 101 Fischer B, Knabbe C, Vollmer T. SARS-CoV-2 IgG seroprevalence in blood donors located in three different federal states, Germany, March to June 2020. *Euro Surveill* 2020; **25**(28).
- 102 Percivalle E, Cambie G, Cassaniti I, et al. Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020. *Euro Surveill* 2020; **25**(24).
- 103 Valenti L, Bergna A, Pelusi S, et al. SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 Milan outbreak. 2020.
- 104 Nesbitt DJ, Jin D, Hogan JW, et al. Low Seroprevalence of SARS-CoV-2 in Rhode Island Blood Donors Determined using Multiple Serological Assay Formats. 2020.

- 105 Thompson CP, Grayson N, Paton R, et al. Detection of neutralising antibodies to SARS coronavirus 2 to determine population exposure in Scottish blood donors between March and May 2020. *medRxiv* 2020: 2020.04.13.20060467.
- 106 Ng D, Goldgof G, Shy B, et al. SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco Bay Area. *medRxiv* 2020.
- 107 Reifer J, Hayum N, Heszkel B, Klagsbald I, Strevva VA. SARS-CoV-2 IgG antibody responses in New York City. *diagnostic microbiology and infectious disease* 2020.
- 108 Doi A, Iwata K, Kuroda H, et al. Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: A cross-sectional study. 2020.
- 109 Takita M, Matsumura T, Yamamoto K, et al. Geographical Profiles of COVID-19 Outbreak in Tokyo: An Analysis of the Primary Care Clinic-Based Point-of-Care Antibody Testing. *J Prim Care Community Health* 2020; **11**: 2150132720942695.
- 110 Takita M, Matsumura T, Yamamoto K, et al. Challenges of community point-of-care antibody testing for COVID-19 herd-immunity in Japan. *QJM* 2020.
- 111 Emmenegger M, Cecco ED, Lamparter D, et al. Population-wide evolution of SARS-CoV-2 immunity tracked by a ternary immunoassay. 2020.
- 112 Fontanet A, Tondeur L, Madec Y, et al. Cluster of COVID-19 in northern France: A retrospective closed cohort study. *medRxiv* 2020: 2020.04.18.20071134.
- 113 Armann JP, Unrath M, Kirsten C, Lueck C, Dalpke A, Berner R. Anti-SARS-CoV-2 IgG antibodies in adolescent students and their teachers in Saxony, Germany (SchoolCoviDD19): very low seroprevalence and transmission rates. 2020.
- 114 Pagani G, Conti F, Giacomelli A, et al. Seroprevalence of SARS-CoV-2 IgG significantly varies with age: results from a mass population screening (SARS-2-SCREEN-CdA). 2020.
- 115 Italy National Institute of Statistics. Primi risultati dell'indagine di sieroprevalenza sul SARS-CoV-2. 2020.
- 116 Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. *eurosurveillance* 2020; **25**(10).
- 117 United Kingdom BioBank. UK Biobank SARS-CoV-2 Serology Study Weekly Report - 21 July 2020. 2020.
- 118 Ward H, Atchison C, Whitaker M, et al. Antibody prevalence for SARS-CoV-2 following the peak of the pandemic in England: REACT2 study in 100,000 adults. 2020.
- 119 United Kingdom Office for National Statistics. Coronavirus (COVID-19) infection survey: characteristics of people testing positive for COVID-19 in England, August 2020. 2020.
- 120 University of Utah Health. Utah HERO project announces phase one findings. 2020.
- 121 U.S. Center for Disease Control and Prevention. Disease Burden of Influenza. 2020.
- 122 Furuya-Kanamori L, Cox M, Milinovich GJ, Magalhaes RJS, Mackay IM, Yakob L. Heterogeneous and Dynamic Prevalence of Asymptomatic Influenza Virus Infections. *Emerging infectious diseases* 2016; **22**(6): 1052-6.
- 123 Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. *Nature* 2020.
- 124 Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA* 2020; **323**(20): 2052-9.
- 125 Azar K, Shen Z, Romanelli R, et al. Disparities in outcomes among COVID-19 patients in a large health care system in California. *Health Affairs* 2020; **39**.
- 126 EuroMoMo. Excess Mortality in Europe. 2020.